We are the leading transatlantic small molecule contract research and manufacturing organization that has been a trusted global partner for biotech and pharma companies for over 30 years.
About us
Why work with us?
Vacancies
A career at Symeres is unlike any other. Groundbreaking research, inspiring clients, motivating projects and being part of talented teams. So if you’re an outstanding talent with a need to discover the solutions to all kinds of fascinating challenges, we want to hear from you.
Latest news
Below are a few of our most recent news items.
-
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, The Netherlands
After months of dedication and collaboration, the official opening of the Marie Curie building at the Pivot Park in Oss was opened on Sep 19th, 2024. The Marie Curie building is a multitenant laboratory building which houses Oncolines B.V., the in vitro biology services laboratory of Symeres. Read more about this exciting development!
Read more
-
J. Med. Chem. Publication: Preclinical Lead Optimization of a 1,2,4-Triazole-Based Tankyrase Inhibitor
In collaboration with Oslo University Hospital, we report the synthesis and biological activity of novel 1,2,3-triazole-based tankyrase inhibitors. Through a modular synthetic pathway and X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.
Read more
-
New video of our Solid-State Center of Excellence
In this new video our colleagues Gabriella Pizutti, Chantalle van Berkel, and Eva Verhofstad, will give you an exciting lab tour through the Symeres Solid-State Centre of Excellence, located at the Symeres site in Weert, the Netherlands. You will learn more about PhysChem Properties, Solid Form Screening, Crystallization, Crystal Habit, Pre-formulation, and Formulation. Feel free to contact us via the contact form on this website if you would like to learn more about our Solid-State capabilities.
Read more
-
Marina Virgili about Barcelona and Groningen
We had the pleasure of sitting down with Marina Virgili, a dynamic and accomplished professional with a fascinating history in the pharmaceutical industry. Originally from the beautiful city of Barcelona, Marina shared insights into her background, career, and the unique experiences she has encountered along the way.
Read more
-
New equipment at Exemplify
Exemplify has recently acquired a Mettler-Toledo EasyMax 402 automated reactor system to add to its process development capabilities. This instrument can accommodate reactor sizes of 100 and 400 mL and allows for the precise automated control of reaction parameters such as temperature, stirring speed, reagent addition rate, and pH, providing real-time data collection that can greatly enhance our understanding of a reaction’s unique profile.
Read more
-
New 100 L vessels in Groningen
The first of the two new 100 L glass-lined stainless steel reactor lines has successfully finished the testing and now it is operational at our Groningen site. By doubling our batch size capacity, we have increased the efficiency for large-scale non-GMP production projects. This will result in faster delivery times for our clients and less batch routine work for our chemists.
Read more
-
Rory Curtis joins Symeres Business Development Team
We are happy to have such an experienced biologist on board to work with our many American clients. In this interview, our new colleague, Rory Curtis, will introduce himself and talk about the journey that led him from London to the city of Buffalo in New York state.
Read more
-
Symeres CEO Eelco Ebbers Speaks on “Leaders in Life Sciences” Podcast
Symeres CEO Eelco Ebbers recently shared his insights on the renowned “Leaders in Life Sciences” podcast, hosted by Henk Jan Out. Recorded at the Pivot Park in Oss, near our subsidiary Oncolines, the interview delved into various facets of Eelco’s journey, including his educational background in organic chemistry, Symeres’ services and strategy, as well as personal interests such as family and hobbies.
Read more
-
Organix: New facility
On March 26th we had the Grand Opening of our brand new, state-of-the-art Organix synthetic and analytical chemistry laboratories in Woburn, just outside Boston MA.
Read more
-
Towards Multitargeted Ligands as Pain Therapeutics: Dual Ligands of the Cavα2δ-1 Subunit of Voltage-Gated Calcium Channel and the μ-Opioid Receptor
In collaboration with WeLab Barcelona, we report the synthesis and biological activity of novel pain therapeutics, which target both Cavα2δ-1 and MOR. One of these disubstituted pyrrolidines demonstrated an analgesic effect in various rodent models of pain, and a lack of unfavorable off-target interactions, showing no evident signs of withdrawal or tolerance. Click on the link below for a short summary of this publication.
Read more
-
Innovative macrocycles as powerful Mcl-1 inhibitors
This is a recap of the article “Development of potent Mcl-1 inhibitors: structural investigations on macrocycles originating from a DNA-encoded chemical library screen” published in the Journal of Medicinal Chemistry. Myeloid cell leukemia 1 (Mcl-1) is a protein that plays a crucial role in the regulation of cell survival and cell death. It is part of a family of proteins called the Bcl-2 family, which are known for their involvement in controlling the life span of cells.
Read more
-
Oncolines unveils new State-of-the-Art Laboratories
In a significant stride towards advancing cancer research and drug development, Oncolines, has officially received the keys to its new laboratories and offices situated within the prestigious Curie Building on the Pivot Park in Oss, the Netherlands.
Read more
-
Our Article Published in the Journal of Medicinal Chemistry
Symeres is thrilled to announce the publication of a scientific article in the prestigious Journal of Medicinal Chemistry with our colleague Koen Hekking as the main author and many more Symerians involved! We are incredibly proud of our colleagues who were instrumental in the research and development of this innovative project.
Read more
-
Peter Molenveld Assumes Role as Secretary of KNCV (Royal Netherlands Chemical Society)
Symeres is proud to announce that our colleague Dr. Peter Molenveld has been appointed as a board member of the Royal Netherlands Chemical Society (KNCV). His appointment as Secretary marks a crucial milestone in Molenveld’s career and signifies his commitment to advancing the interests of the chemical community in the Netherlands.
Read more
-
Luc van Hijfte Assumes Presidency of EFMC, Spearheading Advances in Medicinal Chemistry and Chemical Biology
Symeres is thrilled to announce that as of January 1, 2024, our sr. Vice President Dr. Luc van Hijfte has taken the helm as the President of the European Federation of Medicinal Chemistry and Chemical Biology (EFMC).
Read more
-
Interview with the Computer-Aided Drug Design (CADD) Department
Our Computer Aided Drug Design department supports our clients’ drug discovery projects with some of the best (predictive) software.
Read more
-
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.” Dooyoung Jung, CEO of Pinotbio.
An in-depth interview with Doo Young Jung, the founder and CEO of our client Pinotbio in South Korea, focused on the challenge of cancer resistance/relapse
Read more
-
New scientific services from Symeres
We’re proud to announce that our brand new CMC facility at the Exemplify site of Symeres in New Jersey has been successfully completed. GMP drug product R&D facilities that will allow it to provide end-to-end services ranging from GMP and non-GMP drug product development to phase 1 and 2 clinical supplies of various oral, parenteral, and topical formulation dosage forms.
Read more
-
Interview with the new Managing Director of Symeres Groningen
On October 2, Dr Melloney Dröge started in her new role as Managing Director for the Groningen site.
Read more
-
Chiral Chemistry: in the DNA of Symeres
Over 50% of current drugs in development are chiral. At Symeres we apply a suite of state-of-the-art technologies to obtain the desired chiral compound in high enantiomeric purity. For decades, Symeres has been supporting the global pharma and biotech industry with the synthesis and delivery of chiral compounds, both through synthesis and purification strategies.
Read more
Latest events
Symeres actively participates in many international Life Sciences conferences. See below for some of the upcoming events where you can meet us and discuss your R&D services needs.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
